Clinical trials: Thrombolytic (t-PA) Treatment
Ischemic Stroke
Rt-PA Thrombolytic Therapy in Combination With Remote Ischemic Conditioning for Acute Ischemic Stroke
The purpose of this study is to determine the safety and feasibility of remote limb ischemic conditioning(RIC) in acute ischemic stroke patients who received r-tPA thrombolytic therapy.
- Trial name
- NCT03231384
- Testing
- Remote ischemic conditioning
- Where
- China
- Volunteers
- 31 people
- Sponsor
- Capital Medical University
Acute Ischemic Stroke, rhTNK-tPA
Observational Study to Assess the Safety of rhTNK-tPA (Mingfule®) vs. Rt-PA (Actilyse®) in Treating Acute Ischemic Stroke
This is a multicenter, prospective, non-randomized, post-marketing safety surveillance cohort study with rt-PA (Actilyse®) as the control.
- Trial name
- NCT07519889
- Testing
- rhTNK-tPA, rt-PA
- Volunteers
- 4,500 people
- Sponsor
- CSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd.
Central Retinal Artery Occlusion
Early Reperfusion Therapy With Intravenous Thrombolysis for Recovery of VISION in Acute Central Retinal Artery Occlusion
Non-arteritic, thromboembolic central retinal artery occlusion (CRAO) is an acute neurovascular-ophthalmological emergency which leads to severe and permanent vision loss; no evidence-based therapy does exist.
- Trial name
- REVISION (NCT04965038)
- Testing
- Tenecteplase (until trial protocol V04: Alteplase)
- Where
- Germany
- Volunteers
- 127 people
- Sponsor
- University Hospital Tuebingen
Ischemic Stroke
Extending the Time for Thrombolysis in Emergency Neurological Deficits - Intra-Arterial
Patients presenting to the emergency department with acute ischaemic stroke, who are eligible for standard intravenous tPA therapy within 4.5 hours of stroke onset will be assessed for "dual target" major vessel occlusion and…
- Trial name
- EXTEND-IA (NCT01492725)
- Testing
- Intra-arterial Clot Retrieval with Solitaire device, intravenous tissue plasminogen activator (tPA)
- Where
- 9 sites in Australia, New Zealand
- Volunteers
- 70 people
- Sponsor
- Neuroscience Trials Australia
Thrombosis
Ex Vivo Test of New Stroke Treatment Using Magnetic Nanorobots
Tissue plasminogen activator (tPA) is the FDA approved thrombolytic drug for patients with acute ischemic stroke. While transcatheter endovascular therapy is widely accepted as an effective method for targeted blood vessels via a…
- Trial name
- NCT04644653
- Where
- 2 sites in Hong Kong
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Chinese University of Hong Kong
Ischemic Stroke, Thrombolytic (t-PA) Treatment
Long-Term Survival After Ischaemic Stroke: Ebrictus Study
A number of large trials have confirmed the benefits of thrombolysis in acute stroke, but there are gender differences. The authors sought to examine the relationship between sex and outcome after thrombolysis.
- Conditions
- Ischemic Stroke, Thrombolytic (t-PA) Treatment, Gender Bias, Long Term Adverse Effects
- Trial name
- EBRICTUS (NCT03247036)
- Testing
- IV thrombolytic (t-PA) treatment vs not
- Where
- Spain
- Volunteers
- 21,000 people
- Sponsor
- Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina
Acute Ischemic Stroke
Phase III Clinical Trial of rhTNK-tPA in Treating Acute Ischemic Stroke With Extended Time Window.
This is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study designed to evaluate the efficacy of recombinant human tissue-type plasminogen activator variant (rhTNK-tPA) (0.25 mg/kg, maximum dose…
- Trial name
- TRACE-LATE (NCT07201688)
- Testing
- rhTNK-tPA
- Where
- China
- Volunteers
- 890 people
- Sponsor
- CSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd.
Stroke
Intravenous Thrombolysis Plus Hypothermia for Acute Treatment of Ischemic Stroke
The purpose of this trial is to evaluate if it is safe to use tissue plasminogen activator (tPA) within 6 hours of stroke onset when combined with hypothermia.
- Trial name
- NCT00283088
- Testing
- hypothermia, tissue plasminogen activator
- Where
- 7 sites in United States
- Volunteers
- 130 people
- Sponsor
- University of California, San Diego
Acute Ischemic Stroke
Thrombolysis Treated With TNK-tPA in Acute Ischemic Stroke Patients （3T Stroke-II）
The trial is prospective, block randomized, open-label, blinded endpoint (PROBE) design. Patients with acute ischemic stroke, who are eligible for standard intravenous thrombolysis within 4.5 hours of stroke onset will be…
- Trial name
- NCT05281549
- Testing
- Alteplase, Tenecteplase
- Where
- 28 sites in China
- Volunteers
- 225 people
- Sponsor
- Beijing Tiantan Hospital
Acute Ischemic Stroke
Treatment of Acute Ischemic Stroke With Rt-PA Combined With Edaravone Dexborneol
In this study, a multicenter, randomized, controlled, prospective cohort study was conducted to observe the effect of Edaravone Dexborneol on the incidence and outcome of bleeding transformation after thrombolysis in acute…
- Trial name
- TASPE (NCT06248242)
- Testing
- Edaravone dexborneol
- Where
- China
- Volunteers
- 400 people
- Sponsor
- The Second Hospital of Hebei Medical University
ST Elevation Myocardial Infarction
Study of Efficacy and Safety of GNR-060 vs Metalyse in Patients With ST Elevation Myocardial Infarction
GNR-060(JSC "GENERIUM", Russia) is a proposed biosimilar to the referent product Metalyse. This study is to compare the clinical efficacy and safety of GNR-060 vs Metalyse as a thrombolitic agent in patients with with ST…
- Trial name
- NCT05601999
- Testing
- GNR-060, Metalyse
- Where
- 11 sites in Russia
- Volunteers
- 244 people
- Sponsor
- AO GENERIUM
Cerebral Infarction, Brain Ischemia
Japan Alteplase Clinical Trial (J-ACT): Efficacy and Safety Study of Tissue Plasminogen Activator (Alteplase) for Ischemic Stroke
Based on previous studies comparing Duteplase[a recombinant tissue plasminogen activator (rt-PA) very similar to alteplase] doses, we performed a clinical trial with 0.6mg/kg, which is lower than the internationally approved…
- Trial name
- NCT00147316
- Testing
- Alteplase
- Where
- Japan
- Volunteers
- 103 people
- Sponsor
- Tanabe Pharma Corporation
Ischemic Stroke
Stroke Research Consortium in Northern Bavaria (STAMINA)
Each year, approximately 15 million people suffer a stroke worldwide of which 80% are due to ischemic cerebral infarction. Based on the results of randomized controlled trials, treatment options and patient outcomes in acute…
- Trial name
- STAMINA (NCT04357899)
- Testing
- thrombolysis therapy, endovascular therapy, decompressive surgery
- Where
- 2 sites in Germany
- Volunteers
- 3,769 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Post-stroke Seizure, Post-stroke Epilepsy
Post-stroke Seizure and Epilepsy Following Thrombolytic Therapy
This retrospective cohort study was conducted by reviewing the records of consecutive patients referred to Bu Ali Sina Hospital from 2016 to 2023, who were hospitalized with a diagnosis of ischemic stroke.
- Conditions
- Post-stroke Seizure, Post-stroke Epilepsy, Thrombolytic (t-PA) Treatment
- Trial name
- NCT06812000
- Where
- Iran
- Volunteers
- 199 people
- Sponsor
- Mazandaran University of Medical Sciences
Stroke, Acute
The Intravascular Cooling in the Treatment of Stroke 2/3 Trial
The purpose of this trial is to determine whether the combination of thrombolysis and hypothermia is superior to thrombolysis alone for the treatment of acute ischemic stroke.
- Trial name
- ICTuS2/3 (NCT01123161)
- Testing
- hypothermia and anti-shivering treatment, Group1: IV t-PA and normothermia
- Where
- 31 sites in United States, Austria and 1 more
- Volunteers
- 120 people
- Sponsor
- University of California, San Diego
Stroke, Brain Infarction
Study of the Combination Therapy of Rt-PA and Eptifibatide to Treat Acute Ischemic Stroke (CLEAR-FDR)
The primary goal of this trial is to determine if individuals with acute ischemic stroke treated with a full dose of IV recombinant tissue plasminogen activator (rt-PA) plus IV eptifibatide started within 3 hours of symptom onset…
- Trial name
- CLEAR-FDR (NCT01977456)
- Testing
- Eptifibatide
- Where
- 8 sites in United States
- Volunteers
- 27 people
- Sponsor
- Arthur Pancioli
Ischemic Stroke
Comparison of Pre-hospital and In-hospital Iv-tPA Stroke Treatment
This is a comparison of clinical outcomes between a pre-hospital and an in-hospital thrombolysis patient registry.
- Trial name
- NCT02358772
- Testing
- thrombolysis in a pre-hospital setting (STEMO concept)
- Where
- Germany
- Volunteers
- 658 people
- Sponsor
- Charite University, Berlin, Germany
Acute Ischemic Stroke
A Multicenter, Three-Arm, Open-Label, Endpoint-Blinded Randomized Controlled Trial to Evaluate the Optimal Duration of Early Tirofiban After Intravenous Thrombolysis in Acute Ischemic Stroke
Acute ischemic stroke is a leading cause of disability and mortality among dults in China. Although intravenous thrombolysis serves as first-line reperfusion therapy, nearly half of patients fail to achieve vascular…
- Trial name
- INSTANT-2 (NCT07842185)
- Testing
- Tirofiban Injection, No Interventions
- Where
- 10 sites in China
- Volunteers
- 1,482 people
- Sponsor
- Xinqiao Hospital of Chongqing
Pulmonary Embolism
Efficacy and Safety of Half Dose Alteplase Added to Heparine, in Patients With Moderate Pulmonary Embolism
The primary aim of this study is to evaluate whether mid dose (safe dose) of Alteplase in addition to standard treatment with heparin (LMWH) in patients with pulmonary embolism (PE) at intermediate risk, it is effective to…
- Trial name
- MONALYSE (NCT02604238)
- Testing
- Alteplase
- Sponsor
- Azienda U.S.L. 1 di Massa e Carrara
Ischemic Stroke
Tenecteplase Versus Alteplase Before Endovascular Therapy for Ischemic Stroke
Patients presenting to the emergency department with acute ischemic stroke, who are are eligible for standard intravenous tPA therapy within 4.5 hours of stroke onset will be assessed for major vessel occlusion to determine their…
- Trial name
- EXTEND-IA TNK (NCT02388061)
- Testing
- Tenecteplase, Tissue Plasminogen Activator
- Where
- 18 sites in Australia, New Zealand
- Volunteers
- 202 people
- Sponsor
- Neuroscience Trials Australia